Telix Pharmaceuticals (ASX:TLX) said that the US Food and Drug Administration has approved its New Drug Application for Gozellix, the company's prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agent for prostate cancer, according to a Friday filing with the Australian bourse.
Gozellix is designed for PET scanning of PSMA-positive lesions in men with prostate cancer, the filing said.
The agent offers a six-hour shelf life and extended distribution range compared to existing gallium-based imaging agents, improving access to PET scanners which currently cannot use other PSMA imaging products, filing added.
Telix expects Gozellix to expand access by qualifying for full reimbursement with reduced or no patient co-insurance, which will benefit underserved populations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。